Oruka Therapeutics, Inc.
NASDAQ Global MarketTotal Valuation
Oruka Therapeutics, Inc. carries a market capitalization of 4.93B, placing it among publicly traded companies globally. Its enterprise value stands at 4.94B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 4.93B |
| Enterprise Value | 4.94B |
Share Statistics
Oruka Therapeutics, Inc. currently has 61.07M shares outstanding.
| Shares Outstanding | 61.07M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 5.23 |
| P/TBV Ratio | 5.23 |
| P/FCF Ratio | -51.21 |
| P/OCF Ratio | -51.09 |
Financial Position
Oruka Therapeutics, Inc. maintains a current ratio of 38.51, meaning it holds 38.5x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 38.51 |
| Quick Ratio | 38.03 |
| Debt / Equity | 0.23 |
| Debt / EBITDA | -0.02 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -18.30 |
| Return on Assets (ROA) | -17.76 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Oruka Therapeutics, Inc.'s stock has gained approximately 171.03348% over the past 52 weeks. The 50-day moving average sits at 92.09, while the 200-day moving average is 66.54.
| Beta (5Y) | N/A |
| 52-Week Price Change | 171.03348% |
| 50-Day Moving Average | 92.09 |
| 200-Day Moving Average | 66.54 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -154.94M, while operating income came in at -155.08M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -155.08M |
| Pretax Income | -132.89M |
| Net Income | -132.89M |
| EBITDA | -154.94M |
| EBIT | -155.08M |
| Earnings Per Share (EPS) | -2.45 |
Balance Sheet
Oruka Therapeutics, Inc. holds 873.56M in cash and equivalents against 2.55M in total debt, resulting in a net debt position of -268.47M. Total book value stands at 1.11B, with working capital of 861.59M providing operational flexibility.
| Cash & Cash Equivalents | 873.56M |
| Total Debt | 2.55M |
| Net Debt | -268.47M |
| Equity (Book Value) | 1.11B |
| Book Value Per Share | 18.20 |
| Working Capital | 861.59M |
Cash Flow
Oruka Therapeutics, Inc. produced -100.92M in operating cash flow over the past twelve months. After subtracting -235,000.00 in capital expenditures, free cash flow totaled -101.15M - equivalent to -1.87 per share.
| Operating Cash Flow | -100.92M |
| Capital Expenditures | -235,000.00 |
| Free Cash Flow | -101.15M |
| FCF Per Share | -1.87 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -15.04 |
| FCF Yield | -1.95 |
Stock Splits
Oruka Therapeutics, Inc.'s most recent stock split took place on September 3, 2024 with a 12:1 split ratio.
| Last Split Date | 9/3/2024 |
| Split Ratio | 12:1 |
Scores
Oruka Therapeutics, Inc. posts an Altman Z-Score of 125.68, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 125.68 |